Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemoglobin level variability: associations with mortality.

David T Gilbertson1, James P Ebben, Robert N Foley

  • 1Chronic Disease Research Group, Minneapolis Medical Research Foundation, 914 South 8th Street, Suite S-206, Minneapolis, MN 55404, USA. dgilbertson@cdrg.org

Clinical Journal of the American Society of Nephrology : CJASN
|November 30, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Study on the Use of Real-World Evidence in a Feasibility Assessment of a Randomized Controlled Trial Design to Support the Fulfillment of Pediatric Requirements with the FDA and EMA.

Therapeutic innovation & regulatory science·2026
Same author

Real-World Comparability of Antiresorptive Osteoporosis Treatment Groups Among Treatment-Naïve and Treatment-Experienced Women Ages 55 and Older in the United States.

Clinical epidemiology·2026
Same author

Implementing Accuracy, Completeness, and Traceability for Data Reliability.

JAMA network open·2025
Same author

Advancing Principled Pharmacoepidemiologic Research to Support Regulatory and Healthcare Decision Making: The Era of Real-World Evidence.

Clinical pharmacology and therapeutics·2025
Same author

Re: "Invited commentary: influence of incomplete death information on cumulative risk estimates".

American journal of epidemiology·2025
Same author

Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2024
Same journal

A Patient's Perspective on Arteriovenous Fistula Care and Far-Infrared Radiation Arteriovenous Fistula Therapy.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

A Beacon of Hope: Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Sequential Biomarker Testing in Kidney Transplant Surveillance: How Far Does One Step at a Time Take Us?

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

The Predicting Risk of Cardiovascular Disease Event Equation Meets CKD.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Muscle Cramp Rate, Severity and Burden in Maintenance Hemodialysis Patients: A Yearlong Multicenter Quality Improvement Initiative.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

From Risk Determinants to Clinical Action: Understanding and Implementing the Cardiovascular Kidney Metabolic Syndrome Framework.

Clinical journal of the American Society of Nephrology : CJASN·2026
See all related articles

Hemoglobin level variability in dialysis patients is linked to mortality risk. Persistently low hemoglobin levels, not variability itself, appear to be the main driver of increased death risk in hemodialysis patients.

Area of Science:

  • Nephrology
  • Hematology
  • Clinical Research

Background:

  • Hemoglobin level variability is a growing concern in dialysis patients.
  • Understanding its impact on mortality is crucial for patient care.

Purpose of the Study:

  • To investigate the association between hemoglobin level variability in hemodialysis patients and subsequent mortality.
  • To identify specific hemoglobin level patterns linked to increased mortality risk.

Main Methods:

  • Retrospective national study of 159,720 hemodialysis patients on epoetin therapy.
  • Hemoglobin values categorized as low (<11 g/dl), intermediate (11-12.5 g/dl), and high (>12.5 g/dl).
  • Variability groups classified based on lowest and highest hemoglobin categories over 6 months.

Related Experiment Videos

Main Results:

  • Low-low (L-L) hemoglobin levels showed the highest adjusted hazard ratio for mortality (2.18).
  • Persistently or transiently low hemoglobin levels, and highly variable levels, were associated with increased mortality risk.
  • Persistently or transiently high hemoglobin levels were not linked to increased mortality.

Conclusions:

  • The duration of hemoglobin levels below the target range, rather than variability alone, may be the primary factor increasing mortality risk.
  • Further research is required to elucidate the causal mechanisms and confirm these findings.